Publications by Professor Steve Wedge - ePrints

Browsing publications by Professor Steve Wedge.

Newcastle Authors	Title	Year
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al.	Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile	2024
Dr Elaine Willmore Suzanne Kyle Dr Yan Zhao Huw Thomas Dr Kenneth Rankin et al.	Targeting the MDM2-p53 interaction: Time- and concentration-dependent studies in tumor and normal human bone marrow cells reveal strategies for an enhanced therapeutic index	2024
Professor Gareth Veal Professor Steve Wedge Dr Christopher Bacon Professor Philip Sloan Professor Alastair Greystoke et al.	A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer	2023
Catherine Salvini Benoit Darlot Jack Davison Dr Mathew Martin Dr Susan Tudhope et al.	Fragment expansion with NUDELs – poised DNA-encoded libraries	2023
Duncan Miller Dr Suzannah Harnor Dr Mathew Martin Dr Richard Noble Professor Steve Wedge et al.	Modulation of ERK5 Activity as a Therapeutic Anti-Cancer Strategy	2023
Dr Nahoum Anthony Charlotte Jennings Dr Mathew Martin Dr Richard Noble Nicole Phillips et al.	Targeting cytotoxic agents through EGFR-mediated covalent binding and release	2023
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al.	Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor	2022
Dr Richard Noble Huw Thomas Dr Yan Zhao Professor Steve Wedge	Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma	2022
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al.	An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)	2021
Dr Ian Hardcastle Dr Ruth Bawn Dr Tim Blackburn Dr Celine Cano Dr Sarah Cully et al.	Structure-Based Design of Potent and Orally Active Isoindolinone Inhibitors of MDM2-p53 Protein–Protein Interaction	2021
John Moir Anna Long Dr Beate Haugk Jeremy French Richard Charnley et al.	Therapeutic Strategies Toward Lactate Dehydrogenase Within the Tumor Microenvironment of Pancreatic Cancer	2020
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al.	Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4	2019
Dr Catherine Willoughby Huw Thomas Dr Elaine Willmore Suzanne Kyle Dr Anita Wittner et al.	Selective DNA-PKcs Inhibition Extends the Therapeutic Index of Localized Radiotherapy and Chemotherapy	2019
Professor Ruth Plummer Professor Steve Wedge Professor Gareth Veal	A first-in-human first-in-class (FIC) trial of the monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with advanced solid tumours	2018
Honorine Lebraud Dr Richard Noble Nicole Phillips Dr Yan Zhao Professor Herbie Newell et al.	A highly potent clickable probe for cellular imaging of MDM2 and assessing dynamic responses to MDM2-p53 inhibition	2018
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al.	Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach	2018
Dr Celine Cano Dr Suzannah Harnor Dr Elaine Willmore Professor Steve Wedge	Targeting DNA-PK as a Therapeutic Approach in Oncology	2018
Professor Steve Wedge	Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib	2017
Professor Steve Wedge	A minimum core outcome dataset for the reporting of preclinical chemotherapeutic drug studies: Lessons learned from multiple discordant methodologies in the setting of colorectal cancer	2017
Lucy Gentles Dr Calum Kirk Huw Thomas Professor Steve Wedge Professor Nicola Curtin et al.	An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer	2017
Dr Dominic Jones Professor Martin Noble Professor Steve Wedge Professor Craig Robson Dr Luke Gaughan et al.	Aurora A regulates expression of AR-V7 in models of castrate resistant prostate cancer	2017
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al.	Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines	2017
Stephen Hallett Dr Martyna Pastok Dr Anita Wittner Professor Steve Wedge Professor Martin Noble et al.	Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System	2017
Dr Richard Noble Dr Natalie Bell Dr Helen Blair Huw Thomas Nicole Phillips et al.	Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and burkitt lymphoma	2017
Professor Ruth Plummer Professor Steve Wedge	Clinical development of new drug-radiotherapy combinations	2016
Lan Wang Professor Herbie Newell Professor Steve Wedge	Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation	2016
Dominic Jones Dr Mark Wade Jim Grey Dr Sirintra Nakjang Wenrui Guo et al.	Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy	2015
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2015
Professor Steve Wedge	Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel	2015
Dr Natalie Bell Dr Helen Blair Lisa Price Dr Katrina Wood Professor Hermann Josef Vormoor et al.	Patient-derived xenograft and in vivo bioluminescent modelling of B-cell NHL	2015
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al.	Identification and characterization of an irreversible inhibitor of CDK2	2014
Professor Steve Wedge	Induction of HIF1a influences estrogen receptor expression in ex-vivo culture of tumour tissue	2014
Professor Steve Wedge	Mechanisms that influence tumour response to VEGF-pathway inhibitors	2014
Dr Susan Tudhope Dr Yan Zhao Dr Anita Wittner Annalisa Bertoli Santosh Adhikari et al.	Profiling inhibitors of MDM2: p53 and MDMX: p53 in relation to MDMX protein levels	2014
Matthew Farren Professor Steve Wedge	Tumor Stromal Phenotypes Define VEGF Sensitivity-Response	2014
Annalisa Bertoli Santosh Adhikari Dr Suzannah Harnor Dr Yan Zhao Professor John Lunec et al.	Validation studies with small-molecule modulators of the MDM2/MDMX-p53 binding interaction	2014
Professor Steve Wedge	Anti-tumour and anti-vascular effects of cediranib (AZD2171) alone and in combination with other anti-tumour therapies	2013
Sarah Jane Ross Dr Fadhel Shaheen Dr Luke Gaughan Professor Craig Robson Professor Steve Wedge et al.	AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo	2013
Professor Steve Wedge	Tumour-stromal architecture can define the intrinsic tumour response to VEGF-targeted therapy	2013
Professor Steve Wedge	An evaluation of 2-deoxy-2- [18F]fluoro-D-glucose and 3‟-Deoxy-3‟-[18F]-fluorothymidine uptake in human tumor xenograft models	2012
Professor Steve Wedge	Expression of stromal genes associated with the angiogenic response are not differentiated between human tumour xenografts with divergent vascular morphologies	2012
Professor Steve Wedge	Inhibition of Aurora-B kinase activity confers antitumor efficacy in preclinical mouse models of early and advanced gastrointestinal neoplasia	2012
Dr Aileen Taylor Professor Steve Wedge	The Clinical Development of Molecularly Targeted Agents in Combination With Radiation Therapy: A Pharmaceutical Perspective	2012
Professor Steve Wedge	An antibody targeted to VEGFR-2 Ig domains 4-7 inhibits VEGFR-2 activation and VEGFR-2 dependent angiogenesis without affecting ligand binding	2011
Professor Steve Wedge	Assessing the Activity of Cediranib, a VEGFR-2/-3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR-family	2011
Professor Steve Wedge	Inhibition of PARP-1 by Olaparib (AZD2281) Increasesthe Radiosensitivity of a Lung Tumor Xenograft	2011
Professor Steve Wedge	Guidelines for the welfare and use of animals in cancer research	2010
Professor Steve Wedge	Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model	2010
Professor Steve Wedge	Examining the acute effects of cediranib (RECENTINTM, AZD2171) treatment in tumor models: a dynamic contrast enhanced MRI (DCE-MRI) study using gadopentate	2009
Dr Celine Roche Professor Steve Wedge Professor Herbie Newell Dr Michael Tilby	The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2	2009
Professor Steve Wedge	The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY- 142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts	2009
Professor Steve Wedge	The use and refinement of rodent models in anti-cancer drug discovery: a review	2009
Professor Steve Wedge	Use of a novel Arg-Gly-Asp radioligand, [18F]-AH111585, to determine changes in tumor vascularity after antitumor therapy	2009
Professor Steve Wedge	Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in ApcMin/+ mice	2008
Professor Steve Wedge	Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol)	2008
Professor Steve Wedge	Inhibition of vascular endothelial growth factor signalling using cediranib (RECENTIN; AZD2171) enhances radiation response and causes substantial physiological changes in lung tumour xenografts	2008
Professor Steve Wedge	Inhibition of vascular endothelial growth factor-A signaling induces hypertension: examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy	2008
Professor Steve Wedge	Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity	2008
Professor Steve Wedge	The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis	2008
Professor Steve Wedge	VEGF receptor tyrosine kinase inhibitors for the treatment of cancer	2008
Professor Steve Wedge	Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts	2007
Professor Steve Wedge	Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model	2007
Professor Steve Wedge	AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis	2007
Professor Steve Wedge	Combining radiotherapy with AZD2171, a potent inhibitor of vascular endothelial growth factor signaling: pathophysiologic effects and therapeutic benefit	2007
Professor Steve Wedge	Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase	2007
Professor Robert Wilkinson Professor Steve Wedge	Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors	2006
Professor Steve Wedge	Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer	2006
Professor Steve Wedge	ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model	2006
Professor Steve Wedge	ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity	2005
Professor Steve Wedge	Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach	2004
Professor Steve Wedge	The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma	2004
Professor Steve Wedge	ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity	2004
Professor Steve Wedge	Dynamic Contrast-Enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts	2003
Professor Steve Wedge	Reduced capillary perfusion and permeability in human tumour xenografts treated with the VEGF signalling inhibitor ZD4190: an in vivo assessment using dynamic MR imaging and macromolecular contrast media	2003
Professor Steve Wedge	Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours	2003
Professor Steve Wedge	Complete structure of an Increasing Capillary Permeability Protein (ICPP) purified from Vipera lebetina venom. ICPP is angiogenic via VEGF receptor signaling	2002
Professor Steve Wedge	Novel 4-Anilinoquinazolines with C-7 Basic Side Chains: Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors	2002
Professor Steve Wedge	ZD1839 (“Iressa‟), a Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Model	2002
Professor Steve Wedge	ZD6474 Inhibits Vascular Endothelial Growth Factor Signaling and Growth of a Wide Range of Tumor Models Following Chronic Oral Administration	2002
Professor Steve Wedge	ZM323881, a novel inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) tyrosine kinase activity blocks VEGF-mediated increases in microvascular permeability in vivo	2002
Professor Steve Wedge	Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors	1999
Dr John Lunn Professor Steve Wedge Professor Herbie Newell Professor Alan Calvert	O⁶-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma	1998
Professor Steve Wedge Fiona Chapman Gordon Taylor Huw Thomas Professor Alan Boddy et al.	A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid	1996
Professor Steve Wedge Gordon Taylor Professor Alan Boddy Professor Alan Calvert Professor Herbie Newell et al.	Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement	1995
Professor Steve Wedge Gordon Taylor Professor Herbie Newell	Measurement of 5,10-dideaza-5,6,7,8-tetrahydrofolate (lometrexol) in human plasma and urine by high-performance liquid chromatography	1995
Professor Herbie Newell Professor Steve Wedge	Pharmacokinetics of high molecular weight agents	1993
Professor Steve Wedge	Preclinical evaluation of polymer-bound doxorubicin	1992